Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen    BIIB

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Biogen Idec Inc. : Biogen Sees Positive Results From First Year of MS Treatment Study

share with twitter share with LinkedIn share with facebook
share via e-mail
03/20/2013 | 01:06pm CEST
   By Saabira Chaudhuri 

Biogen Idec Inc. (BIIB) said it has seen positive results from the first year of a two-year late-stage study of its investigational candidate for a type of multiple sclerosis.

Biogen said results from its two-year pivotal Phase 3 "Advance" study of Plegridy, its investigational candidate for relapsing-remitting multiple sclerosis dosed once every two weeks or every four weeks, indicate that Plegridy significantly reduced multiple sclerosis disease activity, including relapses, disability progression and brain lesions, compared with placebo at one year.

"These full first-year results provide a more complete picture of Plegridy and its positive effects on the reduction of relapse, disability progression and lesion development," said Peter Calabresi, director at the Johns Hopkins Multiple Sclerosis Center. "These data suggest that, if approved, Plegridy may offer the benefit of a less frequent dosing schedule, which would be a meaningful advance for people living with multiple sclerosis."

Plegridy--also called peginterferon beta-1a--met the primary endpoint of reducing annualized relapse rate at one year by 36% compared with placebo. It also met its secondary endpoint, reducing the proportion of patients who relapsed by 39% compared with placebo. Additionally, it significantly reduced the number of gadolinium-enhancing lesions by 86% compared with placebo.

Biogen described Plegridy as a new molecular entity in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body, enabling study of a less-frequent dosing schedule. The investigational drug candidate is a member of the interferon class of treatments and, if approved, would be a new addition to this class, which often is used as a first-line treatment for multiple sclerosis.

The latest announcement comes after, in January, Biogen said data from a late-stage trial of Plegridy were positive. At the time, Biogen said the study's primary endpoint was met for both the two-week and four-week dose regimens. Results showed that Plegridy also met the secondary endpoints. It noted that with both dose regimens studied the risk-benefit profile of Plegridy appears to be favorable.

Also in January, Biogen reported its fourth-quarter earnings fell 2.7% as the biotechnology company's preparations to launch a new drug for multiple sclerosis increased expenses and masked revenue growth from its existing multiple sclerosis treatment.

Shares closed Tuesday at $175.61 and were inactive in recent premarket trading. The stock has risen 47% in the past 12 months.

Write to Saabira Chaudhuri at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BIOGEN
10/19BIOGEN INC : quaterly earnings release
10/18 BIOGEN : Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive ..
09/26 BIOGEN : to Report Third Quarter 2017 Financial Results on October 24, 2017
09/25 BIOGEN : Appoints Camille Lee as SVP, Alzheimer’s Disease Therapeutic Area
09/12 BIOGEN : Appoints Sanjay Jariwala as SVP, Worldwide Medical
09/06 BIOGEN : to Present at the Morgan Stanley 15th Annual Global Healthcare Conferen..
08/28 BIOGEN : Featured Company News - IMRALDI(R), Biogen's Version of AbbVie's Humira..
08/28 BIOGEN : Reports New Data from Phase 1b Study of Investigational Alzheimer&rsquo..
08/25 Samsung, Biogen version of AbbVie's Humira approved in Europe
08/25 BIOGEN : IMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is ..
More news
News from SeekingAlpha
10/20 Celgene selloff weighs on biotechs, IBB down 1%
10/19 BIOTECH DEVELOPER STOCKS : What Are The Best Wealth-Builders Now?
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
10/17 VALUE SYSTEM : Amgen Looks Undervalued
10/17 Premarket analyst action - healthcare
Financials ($)
Sales 2017 11 991 M
EBIT 2017 6 193 M
Net income 2017 3 906 M
Debt 2017 3 216 M
Yield 2017 -
P/E ratio 2017 19,40
P/E ratio 2018 16,10
EV / Sales 2017 6,23x
EV / Sales 2018 5,84x
Capitalization 71 485 M
Duration : Period :
Biogen Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Technical analysis trends BIOGEN
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 346 $
Spread / Average Target 2,3%
EPS Revisions
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Alisha A. Alaimo Senior Vice President-US Therapeutic Operations
Gregory F. Covino VP-Finance, Chief Financial & Accounting Officer
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN31.85%71 485
CSL LIMITED38.38%49 894
GRIFOLS SA30.11%17 818